Barbara Voith

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Barbara Voith et al. · Clinical Pharmacology & Therapeutics · 2005 · 652 citations

Medicine, Pharmacokinetics, Pharmacology +16

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

Dagmar Kubitza, Michael Becka, Georg Wensing et al. · European Journal of Clinical Pharmacology · 2005 · 648 citations

Medicine, Pharmacokinetics, Pharmacology +5

A Mechanistic Approach for the Scaling of Clearance in Children

Andrea N. Edginton, Walter Schmitt, Barbara Voith et al. · Clinical Pharmacokinetics · 2006 · 217 citations

Public Health, Child Health, Pediatrics +6

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor in healthy subjects

Wolfgang Mueck, Michael Becka, Dagmar Kubitza et al. · International Journal of Clinical Pharmacology and Therapeutics · 2007 · 179 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

First Assessment in Humans of the Safety, Tolerability, Pharmacokinetics, and Ex Vivo Pharmacodynamic Antimalarial Activity of the New Artemisinin Derivative Artemisone

Johannes Nagelschmitz, Barbara Voith, Georg Wensing et al. · Antimicrobial Agents and Chemotherapy · 2008 · 96 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13